The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer

By D. Kalinowski, D. Richardson. Pharmacological Reviews, 2005

690 citations recorded by the source corpus.

Subfields: Genetics, Hematology, Oncology

View Paper: https://www.semanticscholar.org/paper/f6d79219b31126a400ad66bbbabd16778d9eaf5d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Brent R. Stockwell
2. D. Richardson
3. D. Kalinowski

In Hematology

1. Brent R. Stockwell
2. D. Richardson
3. D. Kalinowski

In Oncology

1. Brent R. Stockwell
2. W. Yang
3. Scott J. Dixon
4. R. Kang
5. D. Tang
6. James A. Olzmann
7. Guido Kroemer
8. M. Conrad

Citations in the corpus

• Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come (2016, background): “As iron is vital to cellular proliferation, cancer cells exhibit a higher level of surface transferrin receptors than normal cells (Richardson and Baker, 1990; Richardson and Baker, 1992; Trinder et al., 1996; Kalinowski and Richardson, 2005).”
• Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. (2008, background): “Indeed, investigators have explored this possibility by testing iron chelators for anticancer properties ( Kalinowski and Richardson, 2005 ).”